|
|
 |
Dr. Liu studies the pathophysiology of heart failure and, in particular, the role of inflammation in disease progression. Using transgenic mouse models, his research team has determined that viral and bacterial infections can accelerate heart failure and coronary heart disease and the team is working to develop vaccines to prevent these effects. Dr. Liu is currently co-leading a large-scale project, called Heart Failure Biomarkers, to identify novel biomarkers of cardiovascular disease and potential therapeutic targets in humans.
|
|
Researcher Information
Scientific Director
CIHR Institute of Circulatory and Respiratory Health
Toronto General Hospital, New Clinical Services Building
11th Floor, Rm. 1266, 585 University Avenue
Toronto, Ontario
Canada M5G 2N2
|
|
|
Dr. Liu is the Heart & Stroke/Polo Chair Professor of Medicine and Physiology at the Toronto General Hospital Research Institute, UHN, and Scientific Director of the CIHR Institute of Circulatory and Respiratory Health. He also directs the Heart & Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research at the University of Toronto, which coordinates cardiovascular research and promotes mentorship and training of the next generation of cardiovascular research leaders. Dr. Liu graduated from the Faculty of Medicine at the University of Toronto in 1978. He has received numerous scientific awards including the Research Achievement Award from the Canadian Cardiovascular Society (2003), Visiting Research Professor Award from the Royal College of Physicians and Surgeons (2005), and the Extramural Award of Merit from the American College of Cardiology (2005). He has served as the scientific program chair for both the Canadian Cardiovascular Society and the Heart Failure Society of America scientific sessions and, recently, was asked by HUPO (Human Proteome Organization) to co-chair the 6th International Initiative on Global Cardiovascular Proteomics to be held in Seoul, Korea in October 2007.
|
|
Researcher Information
Scientific Director
CIHR Institute of Circulatory and Respiratory Health
Toronto General Hospital, New Clinical Services Building
11th Floor, Rm. 1266, 585 University Avenue
Toronto, Ontario
Canada M5G 2N2
|
|
|
|
Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003, 9(9):1187-94.
|
|
|
Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003, 290(19):2581-7.
|
|
|
Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A, Liu PP. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006, 48(9):1733-41.
|
|
|
Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006, 355(3):260-9.
|
|
|
Researcher Information
Scientific Director
CIHR Institute of Circulatory and Respiratory Health
Toronto General Hospital, New Clinical Services Building
11th Floor, Rm. 1266, 585 University Avenue
Toronto, Ontario
Canada M5G 2N2
|
|
|
|
|
Cardiovascular diseases are the most important cause of morbidity and mortality in developed countries, causing twice as many deaths as cancer. Among these diseases, heart failure affects approximately 4.8 million persons in the United States, with about 500,000 new cases diagnosed each year. Mortality rates for heart failure remain high: 30 to 40 percent of patients with advanced disease and five to 10 percent of patients with mild symptoms die within five to 10 years.
send a message
more
Cardiovascular diseases are the most important cause of morbidity and mortality in developed countries, causing twice as many deaths as cancer. Among these diseases, heart failure affects approximately 4.8 million persons in the United States, with about 500,000 new cases diagnosed each year. Mortality rates for heart failure remain high: 30 to 40 percent of patients with advanced disease and five to 10 percent of patients with mild symptoms die within five to 10 years. Therefore, management of the underlying causes of heart failure will significantly reduce the risk of mortality for these patients. Heart failure is due to either of two types of heart defects. Systolic heart failure (SHF) is heart failure due to a defect in the expulsion of blood from the heart while diastolic heart failure (DHF) caused by a stiffening of the heart that results in inadequate filling of the blood into the heart. The management of DHF and SHF differs, therefore, it is important to distinguish the two different types of heart failure. Current diagnostic tools and criteria using symptoms, physical examination, chest radiography or electrocardiography are imprecise in differentiating the two types of heart failure. There is an unmet market need to develop accurate diagnostics for SHF and DHF in order to assist physicians in managing heart failure and decrease the risk of inaccurate diagnosis and subsequent inadequate treatment.
Dr. Peter Liu, a leading cardiologist and scientist at the Toronto General Hospital has discovered a peripheral blood biomarker that can be used to distinguish systolic and diastolic heart failure. Clinically validated patient samples tested have shown significant differences in the expression of this marker.
Potential uses for these markers include the development of clinical laboratory assays for cardiovascular applications. A portfolio of cardiovascular-related biomarkers for different cardiovascular conditions are also available for partnering.
send a message
less
|
|
|
|
ORGANIZATIONS
PROJECTS
RESOURCES
There are no related resources for this profile.
ATTACHMENTS
There are no downloads available for this profile.
OTHER INFORMATION
There is no other information available for this profile.
|
|
|
|
|
|
YOU MAY ALSO BE INTERESTED IN:
CATEGORIES
Disciplinary Focus
Experimental biology and chemistry
Research Paradigm
Focused-scope projects,
Large-scale projects
Core Technology
Nucleic acids:
DNA sequencing,
Gene expression systems,
Genotyping,
Microarrays,
RNA technologies
Sign-up to edit this profile
|
